Clinical Trial

177Lu-JH04 in Patients with FAP-Positive Tumors

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 10, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a pilot study to assess the dosimetry, toxicity and response of 177Lu-JH04, a new FAP-targeted radiopharmaceutical, in patients with FAP-Positive Tumors. All patients underwent 68Ga-FAPI PET/CT for selection and were successively divided into three groups of 3 people each.The three groups received successively an approximately 3.70 GBq (100 mCi), 5.55 GBq (150 mCi) and 7.40 GBq (200 mCi) of 177Lu-JH04 up to 4 cycles.
Trial Details
NCT Number NCT06636617
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Patients with Advanced Metastatic FAP-Positive Tumors
Enrollment 9 participants
Start Date 2024-08-21
Primary Completion 2025-08-31 (estimated)
Study Completion 2025-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-10